Home
This site is intended for healthcare professionals

PMG Academy | Advancing Clinical Expertise: Diagnosing PMG with Confidence

Share

Description

This activity is supported by an independent education grant from ArgenX. This online education program has been designed for healthcare professionals in the United States.

Diagnosing Pediatric Myasthenia Gravis (PMG) is challenging, particularly in younger children who frequently present with seronegative, fluctuating ocular symptoms. Led by Dr. Abigail N. Schwaede, this session provides a practical framework to recognize hallmark presentations, navigate diagnostic testing, and expedite specialist referrals.

Session Highlights

  • Bedside Recognition: Spot fatigability, fluctuation, and asymmetry using high-yield bedside tests such as sustained upgaze, Cogan’s lid twitch, and the ice pack test.
  • Differentiating Mimics: Distinguish PMG from congenital myasthenic syndromes (CMS), noting that pyridostigmine response and RNS decrements alone do not confirm autoimmunity.
  • Stepwise Diagnostic Ladder: Navigate atypical and seronegative cases using a structured serology sequence, cell-based assays, and pediatric-adapted neurophysiology.
  • Referral & Red Flags: Identify critical bulbar and respiratory warning signs requiring emergency care, and refer suspected cases promptly without waiting for antibody results.

Prefer to read? See our Key Clinical Summary Here.

Target Audience

This program is designed for healthcare professionals involved in the diagnosis, treatment, and longitudinal management of pediatric patients with pediatric myasthenia gravis (PMG). Relevant clinicians include pediatric and general neurologists, neuromuscular specialists, pediatricians, and advanced practice providers, including nurse practitioners and physician assistants.

Faculty

Dr. Abigail N. Schwaede, MD, is an Attending Physician in Neurology at Ann & Robert H. Lurie Children’s Hospital of Chicago and Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine. She specializes in pediatric neuromuscular disorders, with expertise in myasthenia gravis and other immune-mediated diseases, as well as Duchenne muscular dystrophy and spinal muscular atrophy. Her research focuses on electrodiagnostic tools and outcome measures in pediatric muscle diseases.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr Abigail Schwaede has the following relevant financial relationships: Consultant, Advisor, Speaker: Biogen & Johnson and Johnson.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 ANCC contact hours.

Pharmacy Continuing Education

Partners designates this continuing education activity for 0.5 contact hour(s) (0.5 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-26-365-H01-P

Type of Activity: Application

PA Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until October 15th 2027. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

This continuing education activity is active starting October 22nd 2026, and will expire on October 15th 2027.

Estimated time to complete this activity: 30 Minutes

Learning objectives

By the end of this educational program HCP's should be better able to:

  1. Recognize and accurately diagnose JMG through timely evaluation of pediatric patients with suspected neuromuscular junction disorders:

Differentiate JMG from congenital myasthenic syndromes, transient myasthenia, and other pediatric neuromuscular conditions with overlapping clinical presentations. Interpret serologic, electrophysiologic, and clinical findings to support diagnosis in atypical or seronegative presentations. Implement appropriate referral and diagnostic pathways to reduce delays in diagnosis and treatment initiation.

  1. Individualize treatment planning and longitudinal management strategies for pediatric patients with JMG across the disease continuum:

Apply patient-specific factors, including age at onset, disease phenotype, symptom burden, and treatment response, to guide management decisions. Monitor disease progression, treatment effectiveness, and evolving care needs to support timely treatment optimization and shared decision-making. Integrate transition planning and multidisciplinary care approaches to support continuity of management from pediatric to adult services.

  1. Incorporate emerging targeted therapies into evidence-informed treatment planning for patients with JMG:

Evaluate the mechanisms of action, clinical evidence, and potential role of emerging targeted therapies within the evolving JMG treatment landscape. Identify patients who may be appropriate candidates for targeted therapeutic approaches based on disease characteristics and treatment goals. Apply emerging evidence to support individualized treatment selection, sequencing, and long-term management decisions in clinical practice.

Similar communities

View all

Similar events and on demand videos

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

Today, we're gonna be talking about diagnosing pediatric myasthenia gravis. My name is Abigail Schwade. I'm a pediatric neuromuscular specialist at Luy Children's Hospital in Chicago, Illinois. We're gonna start with a polling question. A 3 year old has ptosis and a suspected neuromuscular junction disorder. Acetylcholine receptor and musk antibodies are negative, which feature most strongly favors autoimmune pediatric MG over congenital myasthenic syndrome. A symmetrical ptosis with fixed ophthalmoplegia since infancy. B, subacute onset of asymmetric variable ptosis with diplopia. C. Clear improvement on pyridostigmine. D. Decrement on 3 Hz repetitive nerve stimulation. Or E, parental consanguinity. Regarding the answers, we can think about how to differentiate acquired pediatric MG from a genetic disorder, congenital myasthenic syndrome. If I were looking for the best answer, I likely would go towards B, where you have asymmetric and subacute onset of ptosis with diplopia, as that's very, a very typical finding in acquired pediatric MG as opposed to A symmetric ptosis with fixed ophthalmoplesia that's been seen since infancy is more typical of congenital myasthenic syndrome. Then we can go to E, parental consanguinity. Which again points more towards a genetic diagnosis, specifically autosomal recessive conditions. C and D are a little less clear as some congenital myasthenic syndromes can respond to pyridostigmine, as well as some congenital myasthenic syndromes will have that decremental response on repetitive nerve stimulation. And those C and D can also be seen in acquired disease, but I think the best answer overall is likely B. So here we're gonna go over pediatric MG in the United States. And this is first pointing towards the top left corner of the slide where we talk about the incidence as of 2020. And this is per million persons. So patients with commercial versus Medicaid insurance, we have 5.9% versus 8.7. And then the prevalence again per million children, again with commercial versus Medicaid, you can see 25.3 and 37.6% per million children. When we think about uh race and ethnicity, as well as gender, um, there's variable. Data among population of pediatric MG and you also need to think about whether a patient is diagnosed post-pubertally versus pre-pubertally, whereas, uh, prior to 12 years of age, we often see a more similar incidence of, of females versus males or girls versus boys. Whereas in the post-prenatal population, you actually see a higher prevalence of girls or females rather than boys, which mimics really the adult population of MG. In terms of race or ethnicity, there's a wide range of uh populations that can be affected by pediatric MG, but we do see that, uh, black children are affected, um, at a higher rate as, and also this is seen in the Medicaid database, um. Really pointing towards uh different socioeconomic uh statuses. So, like I alluded to in the previous slide, there are two different subpopulations of pediatric MG. We have the prepubertal onset or those who have symptom onset prior to 12 years of age, and then the peri or postpubertal onset where symptoms come on uh after 12 years of age or after reaching puberty. And these populations are very different, and they also have very um different prognosis. So we'll start when you look at the pre-pubertal uh population. They often present predominantly with ocular symptoms. More commonly, they're seronegative, although we can see sero conversion and we often do retest for antibodies within the first few years of diagnosis or if symptoms change over time, and they have a much better prognosis than postpubertal as well as the adult population with a higher chance of spontaneous remission. Um, in terms of the differential, as we alluded to earlier, it's important to consider congenital myasthenic syndrome in the prepubertal population as well as the population across ages. In terms of post-pubertal population, it actually resembles adult MG in many ways. There's a lower chance of spontaneous remission, there's a much higher serropositivity for acetylcholine receptor and other antibodies, and it's more likely to be generalized rather than pure ocular. And like I said previously, there's a much higher female predominance in the post-premarital age, similar to other autoimmune diseases that affect the adult population. Here we're gonna go over a case vignette. Um, here we have Maya, who's 4 years old. Maya is a 4-year-old black girl. Her parents reported 3 months of a droopy left eyelid that is worse in the evening and in photos, sometimes with the eye drifting out. She is otherwise well and developmentally normal. Her pediatrician's exam at 9:00 a.m. is normal, and we can see on that picture on the left in the clinic, whereas we have a picture at 7 p.m. where she has almost complete ptosis of the left eye. What is the most appropriate next step? A, reassure and review in 6 months, B, refer to fertosis surgical management, C, arranged brain MRI and discharge if normal, D, examine for fatigue ability, send acetylcholine receptor antibodies and refer to pediatric neurology and ophthalmology, or E, start prednisolone empirically. So if we think about all these answers, Uh, the most obvious and correct answer would be D, as we're worried about an ocular presentation of pediatric myasthenia with, uh, the variable ptosis that's worse in the afternoon or evening, as well as some element of ophthalmoplesia or uh strabismus with the eye drifting out, um, especially later in the evening. The other answers, um, you know, could be considered when we think about the differential diagnosis, but again, given that, uh, these symptoms are worse in the evening and variable and likely fatigueable, it makes the most sense to rule out or rule in pediatric ocular myasthenia gravis. Again, if there is anything different on the examination, you could consider further workup, but it would make sense again to test for antibodies before considering, considering empirically starting with prednisone or prednisolone. So how do we recognize pediatric MG at the bedside or in our clinic? So there's a couple of tests we can do in the clinic. One I'll point to on the bottom right corner of this slide is the ice pack test or orbital cooling. And we know that neuromuscular transmission improves with cold temperatures and is worsened in warm or hot temperatures. Therefore, if you have ptosis, what you can do is you can hold an ice pack over the top of the eyelid, and you want to again focus on the eye with worse ptosis if they both have ptosis. And then you want to hold it there for about 5 minutes, although this can be very difficult with a pediatric patient, it's as it's somewhat uncomfortable. And what you're looking for with cooling of the eyelid is improvement of ptosis. And that's, that's a fairly sensitive sign, um, and can help you diagnose a patient in the ER in the office, or even at home if you ask the family to try it. The other one that we use commonly is sustained upgaze. And what we're doing is we're having the patient um keep their head forward and in, in a neutral position while we have them look up um towards something, you know, above them or the examiner's finger and you see if they can sustain up gaze for about one minute. And what you're looking at with sustained up gaze is worsening of ptosis with, with sustained looking up or immersion of ptosis with looking up. The other two, we talked about is Kogan's lid twitch, as well as curtain sign, and again, we don't use those as commonly in the clinic, but those are things you can definitely look for when you're evaluating a patient with pediatric MG. And then when we move away from pure ocular symptoms, we want to think, are there any generalized sym symptoms of MG and particularly focus on bullbar symptoms as those can be extremely debilitating and require an emergent visit to the ER. So we ask about any signs of Proximal weakness that's fatigueable. So that would be trouble going up the stairs, trouble rising from a chair, um, or trouble rising off the floor, as well as doing things like brushing your hair or brushing your teeth, which indicates difficulty, uh, with proximal muscles in the arms. In terms of